Abstract: This article presents a closed-form variable-structure control strategy with dual avoidance regions design for collision-free waypoint navigation and trajectory tracking of car-like vehicles ...
Abstract: This document offers an overview of fundamental functionalities within the Python Control Systems Library (python-control), a software tool in Python tailored for designing control systems.
Morning Overview on MSN
Giant snakes are spreading fast and experts say more outbreaks are coming
Across South Florida, giant snakes that once seemed like exotic escapees are now entrenched residents, reshaping ecosystems ...
You might be staring at your budget, wondering how you’re supposed to cover rent, debt, and everything else on $20–$25 an ...
Chinese AI startup’s release is a major update to its open-source model series, aimed at multi-language programming and ...
Cue the Terminator soundtrack; Foundation's Phantom is itching for deployment.
Depending on the position, the summer job can last for 3- 4 months and is carried out between May and September 2026. Please note that these summer job positions are available for B.Sc. or M.Sc.
This tool has been developed using both LM Studio and Ollama as LLM providers. The idea behind using a local LLM, like Google's Gemma-3 1B, is data privacy and low cost. In addition, with a good LLM a ...
When ChatGPT arrived in late 2022, it kicked off an AI boom that hasn't stopped since and showed how powerful natural-language tools could be. Since then, we've seen chatbots, copilots and AI agents ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback